|
|
|
Volumn 49, Issue 1276, 2007, Pages 103-104
|
|
Temsirolimus (Torisel) for advanced renal cell carcinoma
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CLARITHROMYCIN;
HYPERICUM PERFORATUM EXTRACT;
INTERLEUKIN 2;
KETOCONAZOLE;
MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;
PHENYTOIN;
RAPAMYCIN;
RIFAMPICIN;
SORAFENIB;
SUNITINIB;
TEMSIROLIMUS;
DRUG DERIVATIVE;
MAMMALIAN TARGET OF RAPAMYCIN;
PROTEIN KINASE;
PROTEIN KINASE INHIBITOR;
ACUTE KIDNEY FAILURE;
ADVANCED CANCER;
ANEMIA;
ANOREXIA;
ASTHENIA;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
COUGHING;
DIARRHEA;
DISEASE COURSE;
DRUG APPROVAL;
DRUG COST;
DRUG DOSE COMPARISON;
DRUG DOSE INCREASE;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG FORMULATION;
DRUG HALF LIFE;
DRUG HYPERSENSITIVITY;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG RESPONSE;
DYSPNEA;
FEVER;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
HYPERGLYCEMIA;
HYPERLIPIDEMIA;
IMMUNE DEFICIENCY;
INFECTION COMPLICATION;
INTERSTITIAL LUNG DISEASE;
INTESTINE PERFORATION;
KIDNEY CARCINOMA;
MONOTHERAPY;
NAUSEA;
NEUTROPENIA;
PERIPHERAL EDEMA;
PROGNOSIS;
RANDOMIZATION;
RASH;
RECOMMENDED DRUG DOSE;
SHORT SURVEY;
SIDE EFFECT;
STOMATITIS;
SURVIVAL TIME;
THROMBOCYTOPENIA;
WEIGHT REDUCTION;
WOUND HEALING IMPAIRMENT;
ARTICLE;
CANCER STAGING;
DRUG INTERACTION;
ECONOMICS;
ENZYMOLOGY;
INTRAVENOUS DRUG ADMINISTRATION;
KIDNEY TUMOR;
METABOLISM;
PATHOLOGY;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
CARCINOMA, RENAL CELL;
DRUG COSTS;
DRUG INTERACTIONS;
HUMANS;
INFUSIONS, INTRAVENOUS;
KIDNEY NEOPLASMS;
NEOPLASM STAGING;
PROTEIN KINASE INHIBITORS;
PROTEIN KINASES;
SIROLIMUS;
TREATMENT OUTCOME;
|
|
EID: 38449091571
PISSN: 0025732X
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
|
Times cited : (2)
|
|
References (5)
|
